US biotech major Gilead Sciences’ (Nasdaq|: GILD) Kite unit today announced that its CAR T-cell therapy helped patients with relapsed or refractory large B-cell lymphoma (LBCL) live longer than historic treatment.
Detailed results from the overall survival (OS) analysis of the landmark Phase III ZUMA-7 study of Yescarta (axicabtagene ciloleucel [axi-cel]) compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).
Axicabtagene ciloleucel is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze